Viking Therapeutics starts oral VK2735 maintenance dosing trial

Go back to Viking Therapeutics starts oral VK2735 maintenance dosing trial

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

October 6, 2026 7:05 AM EDT

Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735

Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated

SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of... More